How 1 Tiny Hepatitis C Drug Developer Trounced Gilead Sciences, Inc. in 2014

Fool.com Headlines http://ift.tt/1zH7Ltt Shares of Regulus Therapeutics more than doubled this year on the heels of promising early-stage hepatitis C drug trial results.